Radiopharm Theranostics (RDPTF) Invested Capital (2024 - 2026)

Radiopharm Theranostics (RDPTF) has reported Invested Capital for 3 consecutive years, with $341180.9 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital fell 28.94% year-over-year to $341180.9 in Q2 2026; TTM through Jun 2026 was $341180.9, a 28.94% decrease from a year earlier, with the FY2026 full-year figure at $326658.6, down 99.56% from the prior year.
• Invested Capital was $341180.9 for Q2 2026 at Radiopharm Theranostics, down from $480134.2 in the prior quarter.
• Over five years, Invested Capital peaked at $81.5 million in Q4 2024 and troughed at $341180.9 in Q2 2026.
• A 3-year average of $20.7 million and a median of $440343.9 in 2024 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital gained 19.87% in 2025 and fell 28.94% in 2026, its largest moves.
• Over 3 years, Invested Capital stood at $81.5 million in 2024, then sank by 99.41% to $480134.2 in 2025, then slipped by 28.94% to $341180.9 in 2026.
• The last three Invested Capital figures came in at $341180.9 (Q2 2026), $480134.2 (Q2 2025), and $81.5 million (Q4 2024), per Business Quant data.